Is the business good?
How good a business is WGS?
GeneDx Holdings Corp. earns −29% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−29%
Return on invested capital · cost of capital 9.0% · 38 points below what the capital costs: growth destroys value
- Operating margin
- −15%
Operating margin · Diagnostics & Research median 7.1% · 12 months to Q1 2026
- Share count, year on year
- +4.2%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 18%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −135% |
| FY2021 | −210% |
| FY2022 | −284% |
| FY2023 | −89% |
| FY2024 | −7.6% |
| FY2025 | −3.1% |
Details›
- Gross margin12 months to Q1 2026
- 70%
- Operating margin12 months to Q1 2026
- −15%
- Net margin12 months to Q1 2026
- −18%
- Free cash flow margin
- −6.5%
- R&D as % of revenue
- 18%
- Revenue, trailing twelve months
- $443M
- Free cash flow, trailing twelve months
- −$29M
- Net income, trailing twelve months
- −$78M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −29%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Diagnostics & Research
Ranks #28 of 29 by Smart Score